N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea

European Journal of Heart Failure

Volumn 6, Issue 1, 2004, Pages 63-70

  Nielsen, Lene Svendstrup ^a   Svanegaard, Jens ^a   Klitgaard, Niels Anders ^b   Egeblad, Henrik ^c  

^a Section of Cardiology   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Brain natriuretic peptide; Dyspnoea; Heart failure; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; GENERAL PRACTITIONER; HEART FAILURE; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PATIENT REFERRAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; DYSPNEA; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; ROC CURVE;

EID: 0842326399     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2003.10.003     Document Type: Article

References (35)

1. Nielsen L.S., Svanegaard J., Wiggers P., Egeblad H. The yield of a diagnostic hospital dyspnoea clinic for the primary health care section. J Intern Med. 250:(5):2001;422-428.
2. Remes J., Miettinen H., Reunanen A., Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J. 12:(3):1991;315-321.
3. Wheeldon N.M., MacDonald T.M., Flucker C.J., McKendrick A.D., McDevitt D.G., Struthers A.D. Echocardiography in chronic heart failure in the community. Q J Med. 86:(1):1993;17-23.
4. Francis C.M., Caruana L., Kearney P., et al. Open access echocardiography in management of heart failure in the community. BMJ. 310:(6980):1995;634-636.
5. Caruana L., Petrie M.C., Davie A.P., McMurray J.J. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from 'diastolic heart failure' or from misdiagnosis? A prospective descriptive study. BMJ. 321:(7255):2000;215-218.
6. Mair F.S., Crowley T.S., Bundred P.E. Prevalence, aetiology and management of heart failure in general practice. Br J Gen Pract. 46:(403):1996;77-79.
7. Parameshwar J., Shackell M.M., Richardson A., Poole-Wilson P.A., Sutton G.C. Prevalence of heart failure in three general practices in north west London. Br J Gen Pract. 42:(360):1992;287-289.
8. Nielsen O.W., Hilden J., Larsen C.T., Hansen J.F. Cross sectional study estimating prevalence of heart failure and left ventricular systolic dysfunction in community patients at risk. Heart. 86:(2):2001;172-178.
9. Clarke K.W., Gray D., Hampton J.R. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J. 71:(6):1994;584-587.
10. Maeda K., Tsutamoto T., Wada A., Hisanaga T., Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 135:(5 Pt 1):1998;825-832.
11. McDonagh T.A., Robb S.D., Murdoch D.R., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 351:(9095):1998;9-13.
12. Muders F., Kromer E.P., Griese D.P., et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J. 134:(3):1997;442-449.
13. Hunt P.J., Richards A.M., Nicholls M.G., Yandle T.G., Doughty R.N., Espiner E.A. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf). 47:(3):1997;287-296.
14. Groenning B.A., Nilsson J.C., Sondergaard L., et al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J. 143:(5):2002;923-929.
15. Downie P.F., Talwar S., Squire I.B., Davies J.E., Barnett D.B., Ng L.L. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. Clin Sci (Lond). 97:(3):1999;255-258.
16. Karl J., Borgya A., Gallusser A., et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl. 230:1999;177-181.
17. Nakamura M., Endo H., Nasu M., Arakawa N., Segawa T., Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart. 87:(2):2002;131-135.
18. Maisel A.S., Koon J., Krishnaswamy P., et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 141:(3):2001;367-374.
19. Talwar S., Squire I.B., Davies J.E., Barnett D.B., Ng L.L. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. Eur Heart J. 20:(23):1999;1736-1744.
20. Hobbs F.D., Davis R.C., Roalfe A.K., Hare R., Davies M.K., Kenkre J.E. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ. 324:(7352):2002;1498.
21. Cowie M.R., Struthers A.D., Wood D.A., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 350:(9088):1997;1349-1353.
22. Fletcher C.M., Elmes P.C., Fairbairn A.S., Wood C.H. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. BMJ. 2:1959;257-266.
23. Remme W.J., Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 22:(17):2001;1527-1560.
24. Berning J., Steensgaard-Hansen F. Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction. Am J Cardiol. 65:(9):1990;567-576.
25. Kober L., Torp-Pedersen C., Carlsen J., Videbaek R., Egeblad H. An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). TRAndolapril Cardiac Evaluation. Eur Heart J. 15:(12):1994;1616- 1620.
26. Henry W.L., DeMaria A., Gramiak R., et al. Report of the American Society of Echocardiography Committee on nomenclature and standards in two-dimensional echocardiography. Circulation. 62:(2):1980;212-217.
27. Henry W.L., Gardin J.M., Ware J.H. Echocardiographic measurements in normal subjects from infancy to old age. Circulation. 62:(5):1980;1054-1061.
28. Groth S., Dirksen A., Dirksen H., Rossing N. Lung function in a representative population sample of persons 30-70 years of age residents of Copenhagen who had never smoked. Normal values for interindividual and intraindividual variations. Ugeskr Laeger. 148:(48):1986;3207-3213.
29. Clerico A., Del Ry S., Maffei S., Prontera C., Emdin M., Giannessi D. The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med. 40:(4):2002;371-377.
30. Harlan W.R., Oberman A., Grimm R., Rosati R.A. Chronic congestive heart failure in coronary artery disease: clinical criteria. Ann Intern Med. 86:(2):1977;133-138.
31. Davie A., McMurray J. Investigation of left ventricular dysfunction in acute dyspnoea. A 100% sensitivity would be difficult to achieve. BMJ. 315:(7108):1997;604.
32. Marantz P.R., Tobin J.N., Wassertheil-Smoller S., et al. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation. 77:(3):1988;607-612.
33. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995;26(5):1376-1398.
34. Luchner A., Burnett J.C. Jr., Jougasaki M., et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens. 18:(8):2000;1121-1128.
35. Nicholls M.G., Lainchbury J.G., Richards A.M., Troughton R.W., Yandle T.G. Brain natriuretic peptide-guided therapy for heart failure. Ann Med. 33:(6):2001;422-427.